10 430

Cited 9 times in

Comparison of carboplatin- and cisplatin-based concurrent chemoradiotherapy in locally advanced cervical cancer patients with morbidity risks

Authors
 Eun Ji Nam  ;  Maria Lee  ;  Ga Won Yim  ;  Jae Hoon Kim  ;  Sunghoon Kim  ;  Sang Wun Kim  ;  Jae Wook Kim  ;  Young Tae Kim 
Citation
 ONCOLOGIST, Vol.18(7) : 843-849, 2013 
Journal Title
ONCOLOGIST
ISSN
 1083-7159 
Issue Date
2013
MeSH
Aged ; Carboplatin/administration & dosage* ; Carboplatin/adverse effects ; Cisplatin/administration & dosage* ; Cisplatin/adverse effects ; Combined Modality Therapy ; Drug-Related Side Effects and Adverse Reactions/classification ; Drug-Related Side Effects and Adverse Reactions/pathology ; Female ; Follow-Up Studies ; Humans ; Middle Aged ; Neoplasm Recurrence, Local/drug therapy* ; Neoplasm Recurrence, Local/mortality ; Neoplasm Recurrence, Local/pathology ; Neoplasm Recurrence, Local/radiotherapy ; Neoplasm Staging ; Paclitaxel/administration & dosage ; Survival Rate ; Uterine Cervical Neoplasms/drug therapy* ; Uterine Cervical Neoplasms/mortality ; Uterine Cervical Neoplasms/pathology ; Uterine Cervical Neoplasms/radiotherapy*
Keywords
Carboplatin ; Cervical cancer ; Chemoradiotherapy ; Cisplatin
Abstract
BACKGROUND:
The aim of this study was to assess the activity and toxicity of primary carboplatin-based chemoradiotherapy (CarboRT) and to compare CarboRT with cisplatin-based chemoradiotherapy (CisRT) in patients with locally advanced cervical cancer and poor general condition.
PATIENTS AND METHODS:
Fifty-one locally advanced cervical cancer patients with morbidity risks were prospectively enrolled between January 2007 and April 2010. Eligible patients received weekly intravenous CarboRT with carboplatin 100 mg/m2, and a comparison was made with a historical patient group that received weekly CisRT with cisplatin 40 mg/m2.
RESULTS:
Median follow-up was 36 months (range: 4-66 months) in the CarboRT group and 53 months (range: 4-121 months) in the CisRT group. Compared with the historical CisRT group, the CarboRT group showed no statistically significant differences in recurrence (hazard ratio [HR], 1.21; 95% confidence interval [CI], 0.52-2.81) and survival (HR, 1.80; 95% CI, 0.49-6.54). The mean numbers of received cycles of CarboRT and CisRT were 7.5 ± 1.4 and 6.0 ± 1.8, respectively (p < .001). The rates of grade 3-4 toxicity were similar in the two groups.
CONCLUSIONS:
CarboRT was better tolerated than CisRT without compromising tumor response and survival in patients with locally advanced cervical cancer and poor general condition.
Full Text
https://theoncologist.alphamedpress.org/content/18/7/843
DOI
10.1634/theoncologist.2012-0455
Appears in Collections:
1. College of Medicine (의과대학) > Dept. of Obstetrics and Gynecology (산부인과학교실) > 1. Journal Papers
Yonsei Authors
Kim, Sang Wun(김상운) ORCID logo https://orcid.org/0000-0002-8342-8701
Kim, Sung Hoon(김성훈) ORCID logo https://orcid.org/0000-0002-1645-7473
Kim, Young Tae(김영태) ORCID logo https://orcid.org/0000-0002-7347-1052
Kim, Jae Wook(김재욱)
Kim, Jae Hoon(김재훈) ORCID logo https://orcid.org/0000-0001-6599-7065
Nam, Eun Ji(남은지) ORCID logo https://orcid.org/0000-0003-0189-3560
Lee, Maria(이마리아)
Yim, Ga Won(임가원)
URI
https://ir.ymlib.yonsei.ac.kr/handle/22282913/87431
사서에게 알리기
  feedback

qrcode

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.

Browse

Links